Theradiag inks third agreement with ICM
PARIS—Theradiag and the Regional Cancer Institute of Montpellier (ICM) have signed a partnership agreement for the development of microRNA-based theranostics tools to aid in screening for and monitoring colorectal cancer. The collaborated program, known as miCRA, will seek to determine the expression and predictive role of microRNA in patients' responses to radio/chemotherapies for colorectal cancer. In keeping with the arrangement, Theradiag will endeavor to identify relevant biomarkers and develop related theranostic assays. The company has also opened a new laboratory dedicated to applied research for the development of microRNA-based assays within the Cap Alpha incubator in Montpellier. Michel Finance, CEO of Theradiag, said the company is pleased "to have signed a very promising third partnership agreement with the ICM."